OncLive TV

Jonathan Mizrahi, MD, discusses efforts being made to target treatment for patients with metastatic colorectal cancer.

Lyudmila A. Bazhenova, MD, discusses ongoing clinical trials in non–small cell lung cancer that are investigating the utility of immunotherapy.

Joshua Brody, MD, discusses addressing required resistance to immunotherapy in non-Hodgkin lymphoma.

Gregory A. Otterson, MD, discusses data examining immunotherapy alone versus in combination in non–small cell lung cancer.

Erin M. Bertino, MD, discusses the impact of the EGFR-mutated subset analysis of the phase 3 IMpower150 trial on the use of immunotherapy in patients with non–small cell lung cancer.

Jonathan E. Brammer, MD, discusses data that have been reported with inotuzumab ozogamicin (Besponsa) in acute lymphoblastic leukemia (ALL).

Alice S. Mims, MD, discusses the Beat AML Master Trial in acute myeloid leukemia (AML).

Lawrence D. Kaplan, MD, discusses research with bispecific monoclonal antibodies in follicular lymphoma.

Jonathan E. Rosenberg, MD, discusses the phase 3 KEYNOTE-045 trial in advanced urothelial cancer.

Brandon G. Smaglo, MD, FACP, discusses the role of immunotherapy in advanced gastric cancer.

Phat Le, MD, discusses research efforts that are needed to address unmet needs in metastatic colorectal cancer.

Kanwal Raghav, MBBS, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Panayiotis S. Savvides, MD, discusses COVID-19 precautions for patients with lung cancer.

Ivy P. Altomare, MD, discusses investigational agents in immune thrombocytopenia.

Jerald P. Radich, MD, discusses measuring minimal residual disease (MRD) in hematologic malignancies.

Nitika Thawani, MD, discusses identifying the difference between adverse events that are associated with radiation versus COVID-19 symptoms in lung cancer.

Preetesh Jain, MD, PhD, discusses the next steps for a study examining the efficacy of venetoclax in high risk relapsed mantle cell lymphoma.

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.

Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.

Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

David D. Thiel, MD, chair, discusses the measures that are being taken to protect patients and providers from the coronavirus disease 2019 (COVID-19).

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Hope S. Rugo, MD, discusses the results of the phase 3 KEYNOTE-522 trial in triple-negative breast cancer (TNBC).

Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.

Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

Neehar Parikh, MD, discusses the role of radiation in hepatocellular carcinoma (HCC).